Drug Profile
Research programme: anticancer alpha-pharmaceuticals - Ablynx/Algeta
Alternative Names: TTCs - Ablynx/Algeta; Tumour targeting conjugates - Ablynx/AlgetaLatest Information Update: 22 Jun 2018
Price :
$50
*
At a glance
- Originator Ablynx; Algeta
- Class Antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Belgium
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Norway